Optic Glioma
Optic glioma is a rare type of brain tumor that develops on the optic nerve, which can affect vision and may cause symptoms such as blurred vision, vision loss, and eye movement problems.
Optic Pathway Glioma: CHF6467 Eye Drops
We are studying the safety and effectiveness of a new eye drop treatment for children and young adults with optic pathway gliomas. This trial aims to see if it can improve their vision.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 3 and 40 years old?
- Do you have OPG-induced visual damage or type 1 neurofibromatosis (NF-1)?
- Have you had any chemotherapy or radiotherapy in the past 9 months?
- Do you have any eye conditions that might affect vision tests?
- Is your disease stable, with two brain MRI checks done at least 6 months ago?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Nerve Growth Factor
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
UOC Oculistica
La Massimina-Casal Lumbroso, Italy
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.